Healthcare Costs of Inflammatory Bowel Disease in The Biologic Era: A Study Of 2,451 Patients with Twelve years Follow-Up Evaluation Academic Article uri icon


  • Objectives Up-to-date knowledge of healthcare costs (HCC) in patients with inflammatory bowel disease (IBD) in the biologic era is still incomplete. In particular, long-term observational studies of HCC are lacking. We aimed to address this need. Methods Five university-affiliated hospitals in Israel supplied lists of 2,451 true-positive IBD patients (1,605 Crohn's disease, 825 ulcerative colitis, 21 IBD-unclassified). Their health resource utilization data over the time-frame 2003-2014 were obtained from their HMOs through a third party. Patient identity and HMO affiliation were unknown to our investigators. Resources included out-patient consultations, emergency visits, hospitalizations, investigations (imaging, endoscopy), pharmacological treatments and surgical procedures. HCC were computed based on the Ministry of Health Tariff for Health Services (12/2014). Cost data (mean [SD] …

publication date

  • January 1, 2016